Cancer cell panel screening with over 1000 cell lines for faster therapeutic development
Capabilities
Rapid Cancer Cell Panel Screening To Support Oncology Research
Pharmaron’s flexible, start anytime cancer cell panel screening keeps your oncology programs moving forward by eliminating inflexible screening windows and delivering the data you need, when you need it. With rapid turnaround and deep multi omics insights, our platform provides the clarity required to advance your compounds with confidence.
A Cancer Cell Panel Screening Designed for Speed and Flexibility
The screen is designed for speed and flexibility, testing 250 cell lines per month with bi-weekly data delivery and flexible service cycles. With customizable cell line selection, plate layouts, and a minimum order of just 20 cell lines, we offer a platform that is designed to scale screening strategies in real time.
Large, Diverse Cancer Cell Panel with Scalable Screening Capacity
Pharmaron offers one of the industry’s largest cancer cell line panels, comprising of over 1,000 fully validated lines across 30+ cancer types. The panel covers key hematologic and solid tumors, encompassing a broad range of cancer types and diversity.
Bioinformatics Support to Interpret Cancer Cell Panel Screening Results
Pharmaron offers optional bioinformatics support to maximize the value of cancer cell panel screening data. Our bioinformaticians provide interpretation of single‑agent and combination screening results, supporting response pattern analysis, sensitivity profiling, and biomarker exploration.
By integrating screening outputs with relevant molecular and multi‑omics datasets, our bioinformatics team help transform large‑scale cancer cell panel data into structured, decision‑ready insights that guide indication selection, compound prioritization, and next‑step experimental planning.
This plot compares the drug sensitivity profile of Tucatinib with hundreds of reference compounds across diverse cancer cell lines. Strong correlations with known HER2 and EGFR inhibitors confirm Tucatinib’s mechanism of action and target specificity.
The figure demonstrates in house analysis comparing gene expression in tumors that respond to treatment versus those that do not. The data helps identify biomarkers linked to drug sensitivity and resistance, supporting your project with insights required for development of more targeted and effective cancer therapies.
Cancer Cell Panel Screening Insights That Inform Key Research Decisions
Pharmaron’s cancer cell panel screening services are designed to help oncology researchers answer critical questions during early and translational discovery, including:
- Identify suitable cancer cell lines for cellular models
- Identify in vivo models likely susceptible to a compound
- Identify cancer types that respond best to treatment
- Identify predictive biomarkers